title: [New therapeutic approaches to autoimmune diseases].
abstract: Over the past decade, new biological therapies have been developed to treat systemic autoimmune diseases. These new treatments, which target various steps of the immune response, include: B lymphocyte (BL) inhibitors, such as anti-CD20 monoclonal antibodies, BlyS antagonists, and tolerogens that inhibit specific BLs that produce pathogenic antibodies; inhibitors of costimulation between antigen-presenting cells and T lymphocytes (TL), such as monoclonal antibodies against CD40 ligand and CTLA4-Ig (abatecept); TL antagonists, which can inhibit proliferation of autoreactive T cells; cytokine antagonists; chemokine and adhesin antagonists, which inhibit trafficking of immunocompetent cells to target organs. These new approaches are based on a deeper understanding of the autoimmune response.
authors.affiliation: Service de Médecine Interne, Centre National de Référence Lupus et Syndrome des Anticorps Antiphospholipides, CHU Pitié-Salpêtrière, Paris. zahir.amoura@psl.aphp.fr
authors.forename: Zahir
authors.initials: Z
authors.lastname: Amoura
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Piette
mesh_terms: D019138:Antibodies, Blocking / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000187:drug effects / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000276:immunology / Q000628:therapy; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology / Q000628:therapy*; D053264:B-Cell Activating Factor; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018106:CD28 Antigens / Q000187:drug effects / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000276:immunology; D018925:Chemokines / Q000037:antagonists & inhibitors; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008565:Membrane Proteins; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D053264:B-Cell Activating Factor; D018106:CD28 Antigens; D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D007155:Immunologic Factors; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor; C505719:TNFSF13B protein, human; D014409:Tumor Necrosis Factor-alpha